Please enable Javascript
Muscle Invasive Urothelial Carcinoma
Advertisement
RETAIN 1 Trial: Using DNA Damage Repair Mutations to Guide Bladder Cancer Treatment
Daniel M. Geynisman, MD
Muscle Invasive Urothelial Carcinoma
|
January 10, 2025
Dr. Geynisman reviews the RETAIN 1 trial evaluating whether certain patients with MIBC can safely avoid invasive procedures.
View More
Durvalumab Granted Priority Review by FDA for Muscle-Invasive Bladder Cancer Treatment
Brandon Twyford
Muscle Invasive Urothelial Carcinoma
|
December 6, 2024
Durvalumab was granted FDA Priority Review for MIBC, after showing significant survival benefits in the NIAGARA trial.
Read More
High Grade Complication Rates Seen With Post-Robotic Radical Cystectomy
Kaitlyn Kosko
Muscle Invasive Urothelial Carcinoma
|
December 6, 2024
Robotic cystectomy after neoadjuvant immunotherapy shows higher severe complication rates than surgery alone.
Read More
Advancing Neoadjuvant Therapies: Oncolytic Immunotherapy and Nivolumab in MIBC
Roger Li, MD
Muscle Invasive Urothelial Carcinoma
|
December 4, 2024
Dr. Li provides background and insights on the implications of his study on oncolytic immunotherapy with nivolumab for MIBC.
View More
IMvigor011 Exploratory Analysis Reveals OS, DFS Rates of ctDNA-Negative Patients With MIBC
Emily Menendez
Muscle Invasive Urothelial Carcinoma
|
December 3, 2024
IMvigor011 compared the efficacy of atezolizumab with placebo in patients with HR MIBC who remained ctDNA+ post-cystectomy.
Read More
Prognostic Potential of ctDNA in Lymph Node-Positive Bladder Cancer Post-RARC
Brandon Twyford
Muscle Invasive Urothelial Carcinoma
|
December 3, 2024
The study examined the prognostic value of ctDNA as a biomarker in patients with muscle-invasive bladder cancer.
Read More
Exploring Perioperative Therapies and Second-Line Treatments in Bladder Cancer
Shilpa Gupta, MD
Muscle Invasive Urothelial Carcinoma
|
December 30, 2024
The final segment of this roundtable series addresses the future of immunotherapy combinations.
View More
Integrating ctDNA in Bladder Cancer: Emerging Trials and Practical Applications
Shilpa Gupta, MD
Muscle Invasive Urothelial Carcinoma
|
December 30, 2024
The fifth segment of this roundtable series focuses on the use of circulating tumor DNA (ctDNA) in managing bladder cancer.
View More
Adjuvant Therapy Challenges: When to Rechallenge Immunotherapy and Chemotherapy in Bladder Cancer
Shilpa Gupta, MD
Muscle Invasive Urothelial Carcinoma
|
December 30, 2024
In part four of this roundtable, the use of immunotherapy in the adjuvant setting for bladder cancer is discussed.
View More
Emerging Targets in Bladder Cancer: EV Pembro, HER2, and ADC Therapies in Focus
Shilpa Gupta, MD
Muscle Invasive Urothelial Carcinoma
|
December 30, 2024
The third segment of this roundtable series focuses on the latest developments in bladder cancer treatments.
View More
Multidisciplinary Approaches in Bladder Cancer: Bladder Preservation and Chemoradiation
Shilpa Gupta, MD
Muscle Invasive Urothelial Carcinoma
|
December 30, 2024
In part two of this roundtable, multidisciplinary approaches to managing MIBC are discussed.
View More
Bladder Cancer Breakthroughs: Insights from the NIAGARA Trial and Creatinine Cutoff Debate
Shilpa Gupta, MD
Muscle Invasive Urothelial Carcinoma
|
December 30, 2024
The first segment of this roundtable series focuses on the latest developments in MIBC treatment, including the NIAGARA trial
View More
EV/Pembro and New Treatment Options for Metastatic Bladder Cancer
Karine Tawagi, MD
Muscle Invasive Urothelial Carcinoma
|
October 19, 2024
In the final part of this roundtable, Drs. Koshkin and Grivas discuss the use of EV/pembro and which patients are eligible.
View More
ctDNA in MIBC and Adjuvant Treatments Versus Observation
Karine Tawagi, MD
Muscle Invasive Urothelial Carcinoma
|
October 18, 2024
In part five of this roundtable, the panelists explore the use of ctDNA in the TOMBOLA and IMvigor011 trials.
View More
Exploring Bladder-Sparing Treatment Approaches in MIBC
Karine Tawagi, MD
Muscle Invasive Urothelial Carcinoma
|
October 18, 2024
In the fourth part of this roundtable series, the panelists discuss recent updates on bladder-sparing treatments.
View More
Uromigos Live 2024 ADCs in UC Panel Part 5: How to Design Future Trials With Novel ADCs to Change Practice
Thomas Powles, MBBS, MRCP, MD
Muscle Invasive Urothelial Carcinoma
|
October 18, 2024
During the final part of this panel, novel ADCs are explored and analyzed for use in different settings.
View More
Uromigos Live 2024 ADCs in UC Panel Part 4: Novel ADCs Including HER3 and Novel Nectin-4
Thomas Powles, MBBS, MRCP, MD
Muscle Invasive Urothelial Carcinoma
|
October 18, 2024
During the fourth segment of this panel, novel ADCs including HER3, Nectin-4, and BT8009 are analyzed.
View More
Uromigos Live 2024 ADCs in UC Panel Part 3: HER2 ADCs in Bladder Cancer
Thomas Powles, MBBS, MRCP, MD
Muscle Invasive Urothelial Carcinoma
|
October 18, 2024
In the third part of this panel, the use of HER2 ADCs in bladder cancer is explored.
View More
Uromigos Live 2024 ADCs in UC Panel Part 2: Sacituzumab Govitecan and Other TROP-2 ADCs in Bladder Cancer
Thomas Powles, MBBS, MRCP, MD
Muscle Invasive Urothelial Carcinoma
|
October 17, 2024
In the second segment of this panel, the use of sacituzumab govitecan monotherapy and combinations is discussed.
View More
Uromigos Live 2024 ADCs in UC Panel Part 1: The Impact of First-Line Enfortumab Vedotin on the Bladder Cancer Landscape
Thomas Powles, MBBS, MRCP, MD
Muscle Invasive Urothelial Carcinoma
|
October 16, 2024
In the first part of this panel, the use and impact of enfortumab vedotin in the bladder cancer landscape is considered.
View More
Load More
Advertisement
Advertisement
Advertisement